Clinical trial
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone…
NCT00087022 · Heidelberg Pharma AG, Industry · Completed
Key facts
| NCT number | NCT00087022 |
|---|---|
| Title | Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer |
| Official title | A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER) |
| Lead sponsor | Heidelberg Pharma AG, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Biological, Other |
| Interventions | girentuximab, placebo |
| Enrollment | 864 |
| Start date | Jul 1, 2004 |
| Primary completion | Oct 1, 2012 |
| Completion | Oct 1, 2012 |
| First posted | Jul 12, 2004 |
| Last update posted | Nov 27, 2018 |
| Countries | Argentina, Brazil, Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: